Fudan University

🇨🇳China

Country: 🇨🇳China

Ownership: Private

Established: 1905-01-01

Employees: 1K

Market Cap: -

Website: http://www.fudan.edu.cn

Clinical Trials

Camrelizumab Combined With Apatinib in the Treatment of Advanced Sarcomatoid Carcinoma or Carcinosarcoma

Phase 2

Conditions: VEGFR-TKI
Carcinosarcoma
Sarcomatoid Carcinoma
PD-1 Immunotherapy

Interventions: Drug: Camrelizumab Combined With Apatinib

First Posted Date: 2022-03-04

Last Posted Date: 2022-03-04

Lead Sponsor: Fudan University

Target Recruit Count: 45

Registration Number: NCT05265793

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

A Phase II Clinical Trial of Fruquintinib as Third Line Treatment in Advanced Pancreatic Cancer

Phase 2

Conditions: Advanced Pancreatic Carcinoma

Interventions: Drug: Fruquintinib

First Posted Date: 2022-02-25

Last Posted Date: 2022-02-25

Lead Sponsor: Fudan University

Target Recruit Count: 32

Registration Number: NCT05257122

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

R-CDOP Combined With Intrathecal Methotrexate for DLBCL Patients With High-risk of CNS Relapse

Phase 2

Recruiting

Conditions: Diffuse Large B-cell Lymphoma

Interventions: Drug: R-CDOP+intrathecal MTX

First Posted Date: 2022-02-25

Last Posted Date: 2024-11-11

Lead Sponsor: Fudan University

Target Recruit Count: 83

Registration Number: NCT05257018

Locations: 🇨🇳
Cancer Hospital affilicaited to Xinjiang Medical University, Ürümqi, Xinjiang, China
🇨🇳
Dongmei Ji, Shanghai, Shanghai, China

Capecitabine Combined With Lenvatinib and Tislelizumab as Adjuvant Treatment After Resection in Patients With BTC

Phase 2

Recruiting

Conditions: Biliary Tract Cancer

Interventions: Drug: Capecitabine combined with lenvatinib and tislelizumab

First Posted Date: 2022-02-24

Last Posted Date: 2022-04-04

Lead Sponsor: Fudan University

Target Recruit Count: 75

Registration Number: NCT05254847

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China

Efficacy and Safety of Furmonertinib in EGFR-Mutant, PD-L1+ Patients With Locally Advanced or Metastatic NSCLC (FUTURE)

Phase 2

Recruiting

Conditions: Non-Small-Cell Lung Cancer

Interventions: Drug: Furmonertinib (160mg)

First Posted Date: 2022-02-24

Last Posted Date: 2022-08-04

Lead Sponsor: Fudan University

Target Recruit Count: 62

Registration Number: NCT05255406

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Evaluation of Correlations Between Radiologic Features and Pathologic Subtypes of GGO LUAD Via WMS (ECTOP-1011)

Completed

Conditions: Adenocarcinoma of Lung

First Posted Date: 2022-02-23

Last Posted Date: 2023-07-21

Lead Sponsor: Fudan University

Target Recruit Count: 103

Registration Number: NCT05252676

Locations: 🇨🇳
Fudan University Cancer Center, Shanghai, Shanghai, China

Gonadotropin-releasing Hormone Agonist (GnRHa) Plus Letrozole In Young Women With Early Endometrial Cancer

Phase 2

Recruiting

Conditions: Endometrial Neoplasm Malignant Stage I

Interventions: Drug: Megestrol Acetate 160 MG Oral Tablet
Drug: Triprorelin Acetate
Drug: Medroxyprogesterone Acetate 500 MG
Drug: Letrozole 2.5mg

First Posted Date: 2022-02-18

Last Posted Date: 2024-04-23

Lead Sponsor: Fudan University

Target Recruit Count: 104

Registration Number: NCT05247268

Locations: 🇨🇳
Obstetrics and Gynecology Hospital, Fudan University, Shanghai, China

Parsaclisib in Combination With CHOP in Participants With Previously Untreated PTCL

Phase 1

Not yet recruiting

Conditions: CHOP
Parsaclisib
PI3Kδ Inhibitor
PTCL

Interventions: Drug: Parsaclisib
Drug: CHOP

First Posted Date: 2022-02-14

Last Posted Date: 2022-02-14

Lead Sponsor: Fudan University

Target Recruit Count: 30

Registration Number: NCT05238064

Irinotecan Plus Anlotinib or Further in Combination With Penpulimab for Second-line Treatment of mCRC

Phase 2

Recruiting

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: Anlotinib
Drug: Irinotecan
Drug: Penpulimab

First Posted Date: 2022-02-08

Last Posted Date: 2024-07-03

Lead Sponsor: Fudan University

Target Recruit Count: 44

Registration Number: NCT05229003

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Fluzoparib and Abiraterone in the preSurgery Treatment of Prostate Cancer: FAST Trial

Phase 2

Active, not recruiting

Conditions: High-risk Prostate Cancer
Neoadjuvant Therapy

Interventions: Drug: Abiraterone acetate
Drug: Fluzoparib
Drug: Prednisone
Drug: Androgen deprivation therapy
Procedure: Radical Prostatectomy

First Posted Date: 2022-02-04

Last Posted Date: 2023-12-08

Lead Sponsor: Fudan University

Target Recruit Count: 34

Registration Number: NCT05223582

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy